Waters has released MarkerLynx db Application Manager, a metabonomics and biomarker data management tool for its MassLynx 4.1 statistical analysis and database searching software. MarkerLynx db Application Manager offers improved peak detection, enhanced statistical tools, and new dynamic database searching and storage capabilities for the identification of biomarkers, the company said.
Reactome version 14 is available at http://www.reactome.org. New modules and subsections include post-translational modification of proteins, notch signaling, and hormone-sensitive lipase added under lipid metabolism; mitochondrial transcription added under transcription; MAPK cascade added under insulin receptor mediated signaling; and polo-like kinases added under cell cycle, mitosis.
Thermo Electron has released version 7.0 of its Nautilus LIMS for early-stage discovery. Nautilus includes a new archiving function that enables users to automatically transfer data from active tables to archived tables and back again.
Movers & Shakers
Peter Leddy will join Invitrogen as senior vice president of human resources effective July 5. He most recently served as vice president of human resources for the Americas operations of Dell. Leddy will oversee Invitrogen's global HR strategy and report directly to CEO Greg Lucier
General Electric said that Bill Castell, CEO of GE Healthcare, will retire next year. He will be replaced by Joe Hogan upon his retirement. The appointment was included in an announcement about the realigning of GE's businesses.
Thomas McLain has been appointed to the board of directors of the Biotechnology Industry Organization, effective June 21, 2005. McLain is one of 11 new board members, who will each serve two-year terms.
McLain is currently the chairman, CEO and president of Nabi Pharmaceuticals. Prior to joining Nabi Pharmaceuticals in 1998, McLain was employed by Bausch & Lomb.